PMID- 36580225
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20230928
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 192
IP  - 5
DP  - 2023 Oct
TI  - Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in 
      type-2 diabetes mellitus.
PG  - 2189-2195
LID - 10.1007/s11845-022-03262-w [doi]
AB  - BACKGROUND: Sodium-glucose transporter 2 (SGLT-2) inhibitors provide additional 
      benefits besides glycemic control. AIM: This study aims to compare the clinical 
      outcomes of dapagliflozin and empagliflozin. METHODS: This retrospective study 
      evaluated data retrieved from medical records of patients who were under 
      follow-up with the diagnosis of type 2 diabetes mellitus (T2DM) and were started 
      on dapagliflozin or empagliflozin treatment between January 1, 2017, and June 1, 
      2020. Demographic features, comorbidities, clinical features, duration of 
      diabetes, baseline, and follow-up laboratory test results were recorded. The 
      significance level was set at p < 0.05. RESULTS: This study comprised 342 
      patients who are on the treatment with dapagliflozin (n = 228) or empagliflozin 
      (n = 114). The glycosylated hemoglobin a1c (HBA1C) level was significantly 
      decreased in both the dapagliflozin (8.18-7.59, p < 0.001) and empagliflozin 
      (8.35-7.58, p < 0.001) groups. The urine albumin-to-creatinine ratio (ACR) was 
      also decreased in both groups. A decrease in urine ACR was observed independent 
      of using a renin-angiotensin-aldosterone system (RAAS) blocker both in the whole 
      group and in patients with diabetic nephropathy. The time to addition of a new 
      anti-diabetic agent to the treatment was shorter in the dapagliflozin group 
      (14.4 months vs 17.7 months, p = 0.041, respectively). CONCLUSION: Dapagliflozin 
      and empagliflozin are the drugs to choose for renoprotection in diabetics 
      independent of the use of a RAAS blocker. Even the time to addition of a new 
      anti-diabetic agent is longer in the empagliflozin group, head-to-head 
      comparative trials are needed to asess the potential differences in this regard.
CI  - (c) 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in 
      Ireland.
FAU - Dogruel, Hakan
AU  - Dogruel H
AUID- ORCID: 0000-0002-6204-9796
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Akdeniz University, Antalya, 07070, Turkey.
FAU - Atlim, Hatice Tuluce
AU  - Atlim HT
AUID- ORCID: 0000-0002-6676-2847
AD  - Department of Internal Medicine, Faculty of Medicine, Akdeniz University, 
      Antalya, 07070, Turkey.
FAU - Aydemir, Mustafa
AU  - Aydemir M
AUID- ORCID: 0000-0002-5145-0920
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Akdeniz University, Antalya, 07070, Turkey. 
      aydemirmustafa@akdeniz.edu.tr.
FAU - Yilmaz, Nusret
AU  - Yilmaz N
AUID- ORCID: 0000-0002-7494-1562
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Akdeniz University, Antalya, 07070, Turkey.
FAU - Sari, Ramazan
AU  - Sari R
AUID- ORCID: 0000-0002-6989-1492
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Akdeniz University, Antalya, 07070, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20221229
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - HDC1R2M35U (empagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Retrospective Studies
MH  - Glucosides/therapeutic use
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Dapagliflozin
OT  - Diabetes mellitus
OT  - Diabetic nephropathy
OT  - Empagliflozin
OT  - Renoprotection
OT  - Sodium-glucose transporter 2
EDAT- 2022/12/30 06:00
MHDA- 2023/09/28 06:42
CRDT- 2022/12/29 11:19
PHST- 2022/10/17 00:00 [received]
PHST- 2022/12/19 00:00 [accepted]
PHST- 2023/09/28 06:42 [medline]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/29 11:19 [entrez]
AID - 10.1007/s11845-022-03262-w [pii]
AID - 10.1007/s11845-022-03262-w [doi]
PST - ppublish
SO  - Ir J Med Sci. 2023 Oct;192(5):2189-2195. doi: 10.1007/s11845-022-03262-w. Epub 
      2022 Dec 29.